- Home
- GRFX vs NKGN Comparison
GRFX vs NKGN Comparison
Compare GRFX & NKGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GRFX
- NKGN
- Stock Information
- Founded
- GRFX 1981
- NKGN 2017
- Country
- GRFX Hong Kong
- NKGN United States
- Employees
- GRFX N/A
- NKGN N/A
- Industry
- GRFX
- NKGN Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- GRFX
- NKGN Health Care
- Exchange
- GRFX Nasdaq
- NKGN Nasdaq
- Market Cap
- GRFX 11.9M
- NKGN 14.1M
- IPO Year
- GRFX N/A
- NKGN N/A
- Fundamental
- Price
- GRFX $0.23
- NKGN $0.50
- Analyst Decision
- GRFX
- NKGN
- Analyst Count
- GRFX 0
- NKGN 0
- Target Price
- GRFX N/A
- NKGN N/A
- AVG Volume (30 Days)
- GRFX 154.4K
- NKGN 711.5K
- Earning Date
- GRFX 01-01-0001
- NKGN 12-24-2024
- Dividend Yield
- GRFX N/A
- NKGN N/A
- EPS Growth
- GRFX N/A
- NKGN N/A
- EPS
- GRFX N/A
- NKGN N/A
- Revenue
- GRFX $30,019,108.00
- NKGN N/A
- Revenue This Year
- GRFX N/A
- NKGN N/A
- Revenue Next Year
- GRFX N/A
- NKGN N/A
- P/E Ratio
- GRFX N/A
- NKGN N/A
- Revenue Growth
- GRFX N/A
- NKGN N/A
- 52 Week Low
- GRFX $0.14
- NKGN $0.20
- 52 Week High
- GRFX $1.00
- NKGN $4.06
- Technical
- Relative Strength Index (RSI)
- GRFX 43.75
- NKGN 59.45
- Support Level
- GRFX $0.18
- NKGN $0.45
- Resistance Level
- GRFX $0.21
- NKGN $0.55
- Average True Range (ATR)
- GRFX 0.02
- NKGN 0.07
- MACD
- GRFX -0.00
- NKGN 0.00
- Stochastic Oscillator
- GRFX 19.82
- NKGN 47.48
About GRFX Graphex Group Limited each representing 20
Graphex Group Ltd is engaged in the sale of graphene products. It operates in three segments namely, the Graphene Products Segment includes Processing and sale of graphite and graphene-related products; the Landscape Architecture Design Segment includes Providing landscape architecture design; and the catering business focuses on the operation of restaurants. The company derives the majority of its revenue from the sale of graphene products segment.
About NKGN NKGen Biotech Inc.
NKGen Biotech Inc is a biotechnology company developing cell therapies for neurodegenerative and oncological diseases based on activated NK cells. NK cells are part of the human innate immune response system that can selectively identify and destroy abnormal or diseased cells. Its product candidates are based on a proprietary manufacturing and cryopreservation process that produces SuperNKTM (SNK) cells that have shown increased activity as compared to the starting population of NK cells, based on the results of in vitro experiments performed by NKMAX, as defined by parameters such as cytotoxicity, cytokine production and activating receptor expression. SNK cells can be produced in large quantities and cryopreserved while maintaining high levels of cytotoxicity.